Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 1246  

 
   Table of Contents      
LETTER TO EDITOR
Year : 2014  |  Volume : 13  |  Issue : 2  |  Page : 144-145

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings in Nodular Hepatic and Splenic Sarcoidosis


1 Department of Nuclear Medicine and PET, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Date of Web Publication19-Aug-2014

Correspondence Address:
Dr. Bhagwant Rai Mittal
Department of Nuclear Medicine and PET, Postgraduate Institute of Medical Education and Research, Chandigarh - 160 012
India
Login to access the Email id


DOI: 10.4103/1450-1147.139150

PMID: 25191133

Rights and Permissions

How to cite this article:
Agrawal K, Chawla YK, Bhattacharya A, Mittal BR. Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings in Nodular Hepatic and Splenic Sarcoidosis. World J Nucl Med 2014;13:144-5

How to cite this URL:
Agrawal K, Chawla YK, Bhattacharya A, Mittal BR. Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings in Nodular Hepatic and Splenic Sarcoidosis. World J Nucl Med [serial online] 2014 [cited 2019 Jun 25];13:144-5. Available from: http://www.wjnm.org/text.asp?2014/13/2/144/139150

Dear Editor,

A 62-year-old male patient presented with the chief complaint of loss of weight of 1 year duration. There was no history of associated fever. On evaluation, patient had liver parenchymal disease with raised serum alkaline phosphatase. Computed tomography (CT) of abdomen revealed multiple hypo-attenuating lesions in the liver and spleen. The patient underwent F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan [Figure 1]a for characterization of the hepato-splenic lesions. PET/CT scan showed heterogeneous pattern of tracer uptake in the enlarged liver measuring approximately 18 cm in cranio-caudal direction with increased tracer uptake (SUVmax 9.7) in the hypo-attenuating lesions [arrow in the [Figure 1]b and c. Increased FDG uptake with SUVmax 7.3 was also noted in the multiple well-defined hypo-dense nodules of variable sizes (largest measuring 1.8 cm) in the normal sized spleen [Figure 1]b and c. Increased tracer uptake was seen in right level III cervical, multiple enlarged mediastinal [Figure 1]d and e and abdominal lymph nodes. There was no abnormal lung uptake in the scan. In the given clinical context, differential diagnosis of lymphoma or granulomatous disease was made. The biopsy from the liver showed granulomas. Serum angiotensin converting enzyme (ACE) was also raised on further evaluation, thus indicative of sarcoidosis.
Figure 1: Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography maximum intensity projection image (a) heterogeneous tracer uptake in the enlarged liver with increased tracer uptake (SUVmax 9.7) in the hypo-attenuating lesions (arrow in b and c). Increased FDG uptake with SUVmax 7.3 is also noted in the multiple well defined hypo-dense nodules of variable sizes in the normal sized spleen (b and c). Multiple enlarged FDG avid mediastinal (d and e) lymph nodes are also seen

Click here to view


Sarcoidosis is a systemic disease of unknown etiology, which is characterized by noncaseating epitheloid granulomas. Although it primarily affects lungs and hilar lymph nodes; liver, spleen, heart, and bone marrow are common extra pulmonary sites of disease manifestations. [1] The patients with liver and spleen involvement usually are asymptomatic and show normal liver enzyme tests. The commonest clinical finding is hepatosplenomegaly in 15-40% of patients. In advanced disease, jaundice, pruritus, liver failure, ascites, and hepatic encephalopathy may rarely occur. Serum ACE is usually elevated. Furthermore, the radiographic findings of abdominal sarcoidosis are less characteristic. The hepatic sarcoidosis usually manifests with minimal organomegaly in radiographic imaging such as CT and magnetic resonance. Coalescing granulomas become apparent as multiple hypointense or hypo-attenuating nodules relative to adjacent normal parenchyma in only 5-15% of patients. Peripheral enhancement is not seen in these lesions. [2] Although calcification is uncommon, it may be present in long standing disease. [3] Generally, splenic nodules are larger and more common than hepatic lesions. [4] The hypointense and hypo-attenuating liver and spleen nodules of variable sizes ranging from 5 to 20 mm are present in only 10-15% of patients. [2] It is sometimes difficult to differentiate between sarcoidosis and more common diseases, such as metastases and lymphoma. However, in lymphoma lymph node enlargement is more pronounced and the retrocrural lymph nodes are more frequently involved, which were not present in this case. Furthermore, simultaneous hepato-splenic involvement and no other abnormal tracer activity anywhere, except liver, spleen and lymphadenopathy makes diagnosis of metastatic disease less likely. Increased FDG accumulation has been reported in literature in sarcoidosis. Increased metabolism in more unusual sites like liver and spleen, may mimic lymphoma or metastatic disease. [4],[5],[6] However, this unique case may serve as template for pattern recognition in hepatic and splenic sarcoidosis. Thus in patients with hypermetabolic hypo-attenuating lesions in the liver and spleen with associated hypermetabolic lymphadenopathy, possibility of sarcoidosis may be considered, even if pulmonary involvement is absent.

 
   References Top

1.Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-8.  Back to cited text no. 1
    
2.Warshauer DM, Molina PL, Hamman SM, Koehler RE, Paulson EK, Bechtold RE, et al. Nodular sarcoidosis of the liver and spleen: Analysis of 32 cases. Radiology 1995;195:757-62.  Back to cited text no. 2
    
3.Warshauer DM, Lee JK. Imaging manifestations of abdominal sarcoidosis. AJR Am J Roentgenol 2004;182:15-28.  Back to cited text no. 3
    
4.Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994;35:1647-9.  Back to cited text no. 4
    
5.Guglielmi AN, Kim BY, Bybel B, Slifkin N. False-positive uptake of FDG in hepatic sarcoidosis. Clin Nucl Med 2006;31:175.  Back to cited text no. 5
    
6.Nguyen BD. F-18 FDG PET imaging of disseminated sarcoidosis. Clin Nucl Med 2007;32:53-4.  Back to cited text no. 6
[PUBMED]    


    Figures

  [Figure 1]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References
    Article Figures

 Article Access Statistics
    Viewed716    
    Printed33    
    Emailed0    
    PDF Downloaded141    
    Comments [Add]    

Recommend this journal